March Biosciences Secures 28.4M Series A to Advance Therapy for T-Cell Lymphoma
LSTA Stock | USD 2.68 0.07 2.55% |
About 53% of Lisata Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that many traders are impartial. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
Lisata |
By Daniella Parra March Biosciences has closed an oversubscribed 28.4 million Series A financing, led by Mission BioCapital and 4BIO Capital to advance its innovative autologous chimeric antigen receptor T-cell therapy and more, it said. The therapy is aimed at treating T-cell lymphoma, a condition with few treatment options. Additionally, the company partnered with
Read at finance.yahoo.com
Lisata Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Lisata Therapeutics Fundamental Analysis
We analyze Lisata Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lisata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lisata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Lisata Therapeutics is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Lisata Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lisata Therapeutics stock to make a market-neutral strategy. Peer analysis of Lisata Therapeutics could also be used in its relative valuation, which is a method of valuing Lisata Therapeutics by comparing valuation metrics with similar companies.
Peers
Lisata Therapeutics Related Equities
PTIX | Protagenic Therapeutics | 5.95 | ||||
PULM | Pulmatrix | 5.66 | ||||
TPST | Tempest Therapeutics | 3.26 | ||||
GLUE | Monte Rosa | 0.18 | ||||
IMNN | Imunon | 0.24 | ||||
XOMAO | XOMA | 0.28 | ||||
ANTX | AN2 Therapeutics | 0.79 | ||||
LIXT | Lixte Biotechnology | 2.04 | ||||
BPTH | Bio Path | 2.30 | ||||
CADL | Candel Therapeutics | 2.41 | ||||
MBRX | Moleculin Biotech | 3.41 | ||||
RZLT | Rezolute | 3.61 |
Complementary Tools for Lisata Stock analysis
When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |